Trial · NCT04101721
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age | Laser Photocoagulation | 77.8 | Percentage of participants | ||
| Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age | Aflibercept 0.4 mg | 79.6 | Percentage of participants | ||
| Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age | Laser Photocoagulation | 18.5 | Percentage of participants | ||
| Percentage of Participants Requiring Intervention With a Second Treatment Modality From Baseline to Week 52 of Chronological Age | Aflibercept 0.4 mg | 15.1 | Percentage of participants | ||
| Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age | Laser Photocoagulation | 29.6 | Percentage of participants | ||
| Percentage of Participants With Recurrence of ROP Through Week 52 of Chronological Age | Aflibercept 0.4 mg | 39.8 | Percentage of participants | ||
| Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Laser Photocoagulation | % Ocular TEAEs | 25.9 | Percentage of participants | |
| Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Aflibercept 0.4 mg | % Ocular TEAEs | 18.3 | Percentage of participants | |
| Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Laser Photocoagulation | % Ocular TESAEs | 11.1 | Percentage of participants | |
| Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Aflibercept 0.4 mg | % Ocular TESAEs | 6.5 | Percentage of participants | |
| Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs | Laser Photocoagulation | % Systematic TEAEs | 51.9 | Percentage of participants | |
| Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs | Aflibercept 0.4 mg | % Systematic TEAEs | 47.3 | Percentage of participants | |
| Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs | Laser Photocoagulation | % Systematic TESAEs | 7.4 | Percentage of participants | |
| Percentage of Participants With Systematic (Non-ocular) TEAEs and TESAEs | Aflibercept 0.4 mg | % Systematic TESAEs | 12.9 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04101721/results